BeyondSpring Inc.: Business Overview, Financials & Competitive Analysis
BeyondSpring Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical validation in Phase 3 NSCLC trials provides near-term value inflection potential, but cash constraints require near-term financing solutions or regulatory success. Plinabulin demonstrated positive Phase 3 efficacy in NSCLC with meaningful OS benefits and 3-month survival advantage in non-squamous subgroups, supporting regulatory pathway advancement. However, Q3 2025 financials show.
What is BeyondSpring Inc.'s industry? BeyondSpring Inc. (beyondspringpharma.com) operates in Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation. AskCyborg classifies BeyondSpring Inc. under Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation in its company registry.
BeyondSpring is a clinical-stage biopharmaceutical company focusing on cancer therapy development through its Plinabulin pipeline and TPD (target protein degradation) platform. Recent Phase 3 DUBLIN-3 trial results sh...
Cyborg Score thesis
Clinical validation in Phase 3 NSCLC trials provides near-term value inflection potential, but cash constraints require near-term...
Read the full analyst-debate transcript →Get the Latest BeyondSpring Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBeyondSpring Inc. Overview
Pro stress-test →BeyondSpring is a clinical-stage biopharmaceutical company focusing on cancer therapy development through its Plinabulin pipeline and TPD (target protein degradation) platform. Recent Phase 3 DUBLIN-3 trial results showed plinabulin plus docetaxel achieved median OS of 10.8 vs 8.8 months in Asian NSCLC patients, demonstrating clinical proof-of-concept.
Strategic Profile
Pro stress-test →Plinabulin's mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. BeyondSpring co-founded SEED Therapeutics (38% ownership) which closed a $30M Series A-3 with FDA and NMPA IND clearance.
Competitive Landscape
Pro stress-test →In NSCLC immunotherapy resistance space, few approved options exist despite 60% of patients developing resistance. Competitors include established checkpoint inhibitor companies (Merck, Bristol-Myers Squibb) and other IO combinations in development. BeyondSpring's dendritic cell maturation mechanism differentiates from conventional approaches.
Industry Context
BeyondSpring Inc. operates in Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation.
Key facts
Founded: 2010 · Headquarters: Florham Park, New Jersey, US